Photo by velganos7 from unsplash
Therapy-related Myelodysplastic Syndrome (t-MDS) accounts for up to 20% of all MDS cases and its prevalence is expected to grow as more cancer patients survive. Unfortunately, the prognosis for t-MDS… Click to show full abstract
Therapy-related Myelodysplastic Syndrome (t-MDS) accounts for up to 20% of all MDS cases and its prevalence is expected to grow as more cancer patients survive. Unfortunately, the prognosis for t-MDS remains poor with 5-year overall survival rates
Keywords:
related myelodysplastic;
elimination runx1;
3005 elimination;
myelodysplastic syndrome;
therapy related
Journal Title: Experimental Hematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Experimental Hematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!